Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 3, 2003 - Issue 2
Submit an article Journal homepage
76
Views
24
CrossRef citations to date
0
Altmetric
Review

Origin and utility of the reverse dot–blot

Bert Gold Human Genetics Section, Laboratory of Genomic Diversity, National Cancer Institute at Frederick, Building 560, Room 11–85, Frederick, MD 21702, USA. [email protected]
Pages 143-152 | Published online: 09 Jan 2014

References

  • Rabinow P Making- PCR: a Story of Biotechnology University of Chicago Press, Chicago, IL, USA (1996).
  • •An excellent sanctioned, popular recounting of the story of the early days of Polymerase Chain Reaction from an anthropological viewpoint. The social history is excellent although the anthropological insight is limited.
  • Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. j Mal Biol. 98,503–517 (1975).
  • Erlich H, Bugawan T, Begovich AB et al HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur. Immunogenet. 18, 33–55 (1991).
  • Durica DS, Schloss JA, Crain WR Jr. Organization of actin gene sequences in the sea urchin: molecular cloning of an intron-containing DNA sequence coding for a cytoplasmic actin. Proc. Natl Acad. Li. USA 77, 5683–5687 (1980).
  • Orr WC, Timberlake WE. Clustering of spore-specific genes in Aspergillus nidulans. Bon Natl Acad. Li. USA 79,5976–5980 (1982).
  • Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: a Laboratoty Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (1982).
  • Saiki RK, Scharf S, Faloona F eta]. Enzymatic amplification of P-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350–1354 (1985).
  • Zhang Y, Coyne MY, Win SG, Levenson CH, Kawasaki ES. Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonudeotides. Nucleic Acids Res. 19, 3929–3933 (1991).
  • ••Technically detailed and revealingdiscussion of the considerations for attachment of oligonucleotide probes to solid supports using EDC chemistry Worth reading if only for the detailed controls and experimental design.
  • Saiki RK, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified 3-globin and HLA-DQ a—DNA with allele-specific oligonucleotide probes. Natute324, 163–166 (1986).
  • Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in rdtm the polymerase chain reaction. Gold Spring Ranh Symp. Quant. Biol. 51, 263–273 (1986).
  • Saiki RK, Gelfand DH, Stoffel S eta]. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487–491 (1988).
  • Newton CR, Graham A. PCR. Bios Scientific Publishers in association with the Biochemical Society, Oxford, UK (1994).
  • Innis, MA, Gelfand DH, Sninsky JJ. PCR Strategies, Academic Press, San Diego, CA, USA (1995).
  • Saiki RK, Scharf S, Faloona F etal Enzymatic amplification of fi-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia 1985. BioTechnology24, 476–480 (1992).
  • Li HH, Gyllensten UB, Cui XF, Saiki RK, Erlich HA, Arnheim N. Amplification and analysis of DNA sequences in single human sperm and diploid cells. Nature 335, 414–417 (1988).
  • Embury SH, Scharf SJ, Saiki RK eta]. Rapid prenatal diagnosis of sickle cell anemia by a new method of DNA analysis. N. Engl. Med 316, 656–661 (1987).
  • Saik RK, Chang CA, Levenson CH etal Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. N Engl. j Merl 319, 537–541 (1988).
  • Maggio A, Giambona A, Cai SP, Wall J, Kan YVV, Chehab FE Rapid and simultaneous typing of hemoglobin S, hemoglobin C and seven Mediterranean 3-thalassemia mutations by covalent reverse dot—blot analysis: application to prenatal diagnosis in Sicily. B/ooc/81, 239–242 (1993).
  • Dozy AM, Cai SP, Chehab F, Kan YVV. The use of direct gene analysis to define 3-thalassemia. Ann. NY Acad. Sci. 612, 22–30 (1990).
  • Chehab FF, Der Kaloustian V, Khouri FP, Deeb SS, Kan YVV. The molecular basis of 3-thalassemia in Lebanon: application to prenatal diagnosis. B/ooc/69, 1141–1145 (1987).
  • Chehab FF, Khouri FP, Deeb SS. Globin synthetic ratios in homozygous 3-thalassemia patients from Lebanon. Hemoglobin 8, 151–162 (1984).
  • Cai SP, N J, Kan YVV, Chehab FE Reverse dot—blot probes for the screening offi-thalassemia mutations in Asians and American blacks. hrun2 IVIutat 3, 59–63 (1994)
  • Dianzani I, Landegren U, Camaschella C, Ponzone A, Piazza A, Cotton RG. Fifth International Mutation Detection Workshop, May 13–16, 1999, Vicoforte, Italy. Hum. Mutat. 14, 451–453 (1999).
  • Gold B. DNA genotyping. Adv. Gun. Chem. 36, 171–234 (2001).
  • •A recent review of genotyping methods that discusses the RDB in context with a variety of other molecular diagnostic techniques.
  • Yang YP, Corley N, Garcia-Heras J. Reverse dot—blot hybridization as an improved tool for the molecular diagnosis of point mutations in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Mal Diagn. 6,193-199 (2001).
  • Groman JD, Meyer ME, Wilmott RVV, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl. I Merl 347, 401–407 (2002).
  • Strom CM, Huang D, Chen C eta]. Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. Genet. Merl 5, 9–14 (2003).
  • •Recent work from Quest DiagnosticsNichols Institute that discusses some of the analytic advantages of DNA sequencing in a high mutation spectrum disease. It almost makes it appear cost effective to provide genotype through high-throughput sequencing, but the cost figures are not evident in the publication.
  • Shuber AP, Michalowsky LA, Nass GS eta]. High-throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes. Hum. Mal Genet. 6, 337–347 (1997). This is the method still used by Genzyme Genetics for CF mutation screening. Well worth reading for the clarity of Tony Shuber's technical discussion.
  • Deng GR. A sensitive non-radioactive PCR-RFLP analysis for detecting point mutations at 12th codon of oncogene c-Ha-rosin DNAs of gastric cancer. Nucleic Acids Res. 16, 6231 (1988).
  • Deng GR. [Relation of c-Ha-ms point mutation to the prognosis and metastasis of gastric carcinoma]. Zhonghua Yi Xue Za Zhi 69, 438-442, 432 (1989).
  • Maeda M, Murayama N, Ishli H etal. A simple and rapid method for HLA-DQA1 genotyping by digestion of PCR- amplified DNA with allele specific restriction endonucleases. Tissue Antigens34, 290–298 (1989).
  • Olerup 0. HLA class II typing by digestion of PCR-amplified DNA with allele- specific restriction endonucleases will fail to unequivocally identify the genotypes of many homozygous and heterozygous individuals. Tissue Antigens36, 83–87 (1990).
  • Uryu N, Maeda M, Ota M, Tsuji K, Inoko H. A simple and rapid method for HLA-DRB and -DQB typing by digestion of PCR-amplified DNA with allele specific restriction endonucleases. Tissue Antigens 35, 20–31 (1990).
  • Inoko H. PCR-RFLP method holds great promise for complete HLA class II genotyping. Tissue Antigens 36, 88–92 (1990).
  • Somerville MJ, Sprysak KA, Hicks M, Elyas BG, Vicen-Wyhony L. An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis. Am. J. Hum. Genet. 65, 924–926 (1999).
  • Jeffrey GP, Chakrabarti S, Hegele RA Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genet. 22, 325–326 (1999).
  • Noll WW, Belloni DR, Stenzel TT, Grody WW. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. Nature Genet. 23, 271–272 (1999).
  • Gomez PS, Parks S, Ries R, Tran TC, Gomez PF, Press RD. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. Nature Genet. 23, 272 (1999).
  • Merryweather-Clarke AT, Pointon JJ, Shearman JD etal. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. The European Haemochromatosis Consortium. Nature Genet. 23, 271 (1999).
  • Press RD. Overestimation of HFE C282Y homozygous hemochromatosis prevalence as the result of a common primer-binding site polymorphism. Mal Diagn. 4, 391–392 (1999).
  • de Villiers JN, Kotze MJ. Significance of linkage disequilibrium between mutation C282Y and a MseI polymorphism in population screening and DNA diagnosis of hemochromatosis. Hood Cells Mal Dis. 25, 250–252; discussion 253–254 (1999).
  • Lyamichev V, Neri B. Invader assay for SNP genotyping. Meth. Mal Biol. 212, 229–240 (2003).
  • de Arruda M, Lyamichev VI, Els PS et al Invader technology for DNA and RNA analysis: principles and applications. Expert Rev Mal Diagn. 2, 487–496 (2002).
  • Nevilie M, Selzer R, Aizenstein B et al Characterization of cytochrome P450 2D6 alleles using the Invader system. Rio Techniques 34–38, 40–33 (2002).
  • Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic and pharmacogenetic applications of the Invader assay. Mal fliagn. 4, 353–364 (1999).
  • Cuppens H, Buyse I, Baens M, Marynen P, Cassiman JJ. Simultaneous screening for 11 mutations in the cystic fibrosis transmembrane conductance regulator gene by multiplex amplification and reverse dot—blot. Mol Cell Probes 6, 33–39 (1992).
  • Kan YVV, Golbus MS, Trecartin R. Prenatal diagnosis of sickle-cell anemia. N Engl. Med. 294, 1039–1040 (1976)
  • Kan YVV, Trecartin RF, Golbus MS, Filly RA. Prenatal diagnosis of P-thalassaemia and sickle-cell anaemia. Experience with 24 cases. Lancet 1, 269–271 (1977).
  • Chehab FF, Doherty M, Cai SP, Kan YVV, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias. Nature 329, 293–294 (1987).
  • Nathan DG. Genes, Blood and Courage: a Boy Called Immortal Swart Belknap Press of Harvard University Press, Cambridge, MA, USA (1995).
  • •A worthwhile, semi-autobiographical, popular read by the man once considered the best doctor in America who now heads the Dana-Farber Cancer Institute.
  • Chehab FF, Wall J. Detection of multiple cystic fibrosis mutations by reverse dot—blot hybridization: a technology for carrier screening. Hum Genet. 89, 163–168 (1992).
  • Wang X, Myers A, Saiki RK, Cutting GR. Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Gun. Chem 48, 1121–1123 (2002).
  • ••Most recent work on the development of a Roche LAp that rivals Genzyme's MASDA in mutation spectrum coverage. Do not miss the online supplementary materials that discuss, for the first time, Roche's proprietary BSA oligonucleotide technology
  • Tung CH, Rudolph MJ, Stein S. Preparation of oligonucleotide-peptide conjugates. Bioconjug. Chem. 2, 464–465 (1991).
  • Dracopoli NC, Haines JL, Korf BR et al (Eds) . Current Protocols in Human Genetics, Wiley, New York, NY, USA (2000).
  • Syvanen AC, Bengtstrom M, Tenhunen J, Soderlund H. Quantification of polymerase chain reaction products by affinity-based hybrid collection. Nucleic Acid s Res. 16, 11327–11338 (1988).
  • Lappin S, Cahlik J, Gold B. Robot printing of reverse dot—blot arrays for human mutation detection.Dagn. 3, 178–188 (2001).
  • ••An effort to chronicle and summarizemany years of laboratory effort on the RDB technique by the largest clinical laboratory in the USA.
  • Lau J, Tolan DR Screening for hereditary fructose intolerance mutations by reverse dot-blot. Mal Celi. f3vbes13, 35–40 (1999).
  • Chan V, Yam I, Chen FE, Chan TK. A reverse dot—blot method for rapid detection of non-deletion a-thalassaemia. Br. J: Haematol. 104, 513–515 (1999).
  • Schollen E, Vandenberk P, Cassiman JJ, Matthijs G. Development of reverse dot—blot system for screening of mitochondrial DNA mutations associated with Leber hereditary optic atrophy. Clin. Chem. 43, 18–23 (1997).
  • Jean J, Blais B, Darveau A, Hiss I. Detection of hepatitis A virus by the nucleic acid sequence—based amplification technique and comparison with reverse transcription-PCR. Appl. Environ. Mcrobiol. 67, 5593–5600 (2001).
  • DeMarchi JM, Richards CS, Fenwick RG, Pace R, Beaudet AL. A robotics-assisted procedure for large scale cystic fibrosis mutation analysis. Hum. Mutat. 4, 281–290 (1994).
  • ••As mentioned in the text, this was the firstpublished report of an automated spotting procedure for blots. It is worth reading for both the attractive figures and for an understanding of the many controls run by the Baylor group when they screen for CF mutants.
  • Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3, 149–154 (2001).
  • ••This is the publication encompassing thestandards for CF screening in the United States formulated by a joint committee of the American College of Medical Genetics and the American College of Obstetrics and Gynecology Note the two-tiered screening system advocated.
  • Sosnowski RG, Tu E, Butler W F, O'Connell JP, Heller MJ. Rapid determination of single base mismatch mutations in DNA hybrids by direct electric field control. Proc. Natl Acad. Sci. USA 94, 1119–1123 (1997).
  • Kiesewetter S, Macek M Jr, Davis C et al A mutation in CF1R produces different phenotypes depending on chromosomal background. Nature Genet. 5,274–278 (1993).
  • Strom CM, Huang D, Buller A eta]. Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples. Genet. Med. 4, 289–296 (2002).
  • Morin PA, Saiz R, Monjazeb A. High- throughput single nucleotide polymorphism genotyping by fluorescent 5' exonuclease assay. Biotechniques 27, 538–540, 542, 544 passim (1999).
  • ••This is one of several publications but itemphasizes the high-throughput, low-cost and potential for genotyping, as opposed to RNA quantitation. In addition, it was authored by academics rather than the for-profit development houses that invented the TaqMan system. As a result, the cost discussion is among the best in the published.

Websites

  • www.roche-applied-science.com/pack-insert/3253660A.pdf (Viewed February 2003)
  • www.nanogen.com/products-cystic_f1brosis.htm (Viewed February 2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.